Ensituximab
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL |
Chemical Data
C H N O Molecular Weight | ||
Ensituximab is an experimental monoclonal antibody designed for the treatment of cancer. It specifically targets the epidermal growth factor receptor (EGFR), which is often overexpressed in various types of cancer cells, including colorectal cancer and head and neck cancer. Ensituximab works by binding to the EGFR, thereby inhibiting the receptor's function and preventing the cancer cells from growing and proliferating.
Mechanism of Action[edit | edit source]
Ensituximab is a chimeric (mouse/human) monoclonal antibody. It binds to the extracellular domain of the EGFR with high affinity. By binding to EGFR, ensituximab blocks the receptor's ability to activate its downstream signaling pathways, which are crucial for cell growth and survival. This inhibition can lead to apoptosis (programmed cell death) and reduced tumor growth.
Clinical Trials[edit | edit source]
Ensituximab has been evaluated in several clinical trials, primarily focusing on its efficacy and safety in patients with advanced colorectal cancer. These studies have explored its use both as a single agent and in combination with other chemotherapeutic agents. The results from these trials have provided important insights into the potential therapeutic benefits and limitations of ensituximab in treating cancer.
Side Effects[edit | edit source]
Like other EGFR inhibitors, ensituximab can cause side effects, some of which can be severe. Common side effects include skin rash, diarrhea, and an increased risk of infections. Severe side effects may include pulmonary toxicity and infusion-related reactions. Patients receiving ensituximab are closely monitored for these adverse effects during treatment.
Development and Regulatory Status[edit | edit source]
As of the last update, ensituximab remains an investigational drug and has not yet received approval from regulatory bodies such as the Food and Drug Administration (FDA) in the United States. Its development is ongoing, with additional studies needed to further define its safety profile and efficacy in different cancer populations.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
